TXN Systems

TXN Systems is a preclinical-stage biotechnology company focused on developing a new class of cancer therapeutics that target the thioredoxin system. The company's primary approach involves the development of highly selective small molecule inhibitors of Thioredoxin Reductase 1 (TXNRD1), an enzyme that plays a critical role in protecting cancer cells from oxidative stress. By disrupting this essential survival mechanism, TXN Systems aims to induce apoptosis specifically in tumor cells while sparing healthy tissue. The company's technology is built upon decades of research into redox biology and the thioredoxin system conducted at the Karolinska Institutet. TXN Systems is currently advancing its lead candidates through preclinical studies for the treatment of various solid tumors.